Navigation Links
Drug improves survival of colorectal cancer patients, trial results show
Date:1/17/2012

ROCHESTER, Minn. An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

"For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them," says Dr. Grothey. "This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options."

Researchers tested regorafenib in a phase III, randomized, placebo-controlled trial, conducted simultaneously in the United States, Europe, Japan, Australia and China. They looked at survival outcomes in 760 patients whose cancer had progressed despite standard chemotherapy regimens. Regorafenib is a multi-kinase inhibitor, which has the effect of slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways that are activated in tumors.

Researchers found that patients with metastatic colon cancer who were treated with the drug showed a 29 percent increase in overall survival when compared to those treated with placebo. The median length of survival for patients treated with the drug increased from 5 months to 6.5 months, a statistically significant jump. Overall, regorafenib reduced patients' risk of dying from cancer during the trial by 23 percent.

The trial, whose largest group of study participants in the United States was at Mayo Clinic, finished more than a year ahead of schedule.

"Patients with metastatic colorectal cancer who have failed all approved standard therapies have a poor prognosis," says Dr. Grothey. "This is the first and only agent in this setting that has demonstrated statistically significant overall survival benefit."


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New fibrosis classification improves accuracy of diagnosis in hepatitis C
2. Aquatic therapy soon after total knee arthroplasty improves outcomes
3. Long-term inhaled dry powder mannitol improves lung function in CF
4. Walking skills program improves physical function following hip replacement surgery
5. In-utero procedure for birth defect of the diaphragm significantly improves infant survival
6. Planting improves heart rate, stress levels of mentally challenged adults
7. Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
8. Virtual childbirth simulator improves safety of high-risk deliveries
9. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
10. Putting stroke patients in charge improves quality of life
11. Better understanding of neurologic defects improves post-cardiac-arrest discharge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
(Date:3/28/2017)... ... , ... Usually, the impending arrival of warmer weather means the gleeful banishment ... double chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic ... double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a ... time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service ... uses biometric face recognition to enable users to check in and out from ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder ... few medical professionals in the country to sit on the 2017 National Advisory Board ... just 2 years Dr. Harper helped propel the clinic from a small start-up to ...
(Date:3/28/2017)... ... 28, 2017 , ... The Lice Treatment Center® booth at ... was a busy spot this year. Liz Solovay and Adrian Picheny, the firm’s ... among camp communities during the upcoming 2017 camping season. “Lice infestations at some ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The global ... a value of USD 4.5 billion by 2025, according ... Proper closure of injured tissues post operation is a ... leakages occur in 3% to 15% of cases and ... for one third of postoperative deaths in patients. Surgical ...
(Date:3/27/2017)... SINGAPORE , March 27, 2017 ... a digital health and data analytics company, signed ... collaborations for improving healthcare delivery in the region. ... Institute for Global Health Research and Technology (BIGHEART) ... relationship on several topics related to healthcare IT ...
(Date:3/27/2017)... , March 27, 2017  A recent study ... only four freestanding hospitals in the country dedicated to ... and reconstructive surgery, concluded that the Surfacide Helios ® ... integral component in reducing bacterial pathogens not killed by ... were published at the American Burn Association,s 49th Annual ...
Breaking Medicine Technology: